Rybrevant

Rybrevant is the brand name for amivantamab, a human monoclonal antibody that functions as a bispecific antibody targeting both epidermal growth factor receptor (EGFR) and MET. It is designed to bind these receptors on cancer cells, blocking signaling pathways that promote tumor growth and, in addition, can recruit immune cells to destroy target cells. Rybrevant is administered by intravenous infusion and uses a loading-dose strategy during the initial cycle, followed by weekly maintenance infusions, with dose adjustments possible for toxicity.

In the United States, Rybrevant is indicated for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 20 insertion mutations and who have progressed on or after platinum-based chemotherapy. This represents a targeted therapy option specifically for the exon 20 insertion subset, which has shown limited benefit from many other EGFR inhibitors.

Development and regulatory history: Rybrevant was developed by Janssen Biotech in collaboration with Genmab, using Genmab’s DuoBody platform to create a bispecific antibody. It received regulatory approval from the U.S. Food and Drug Administration in 2021, becoming the first approved therapy specifically for NSCLC driven by EGFR exon 20 insertion mutations.

Safety and tolerability: Common adverse events associated with Rybrevant include infusion-related reactions and rash, among others. As with many monoclonal antibodies, patients may require monitoring during infusions and adjustments based on tolerance and safety findings. The exact safety profile is detailed in the prescribing information and is managed by clinicians during treatment.